---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275867"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:25:43.666953+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA

## Summary
- Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.
- Initial response data for >15 refractory RA patients expected 1H 2026; FDA discussions planned.
- Cash, equivalents, investments $123M as of Sep 30, 2025; runway into Q2 2027.
- Q3 R&D expense $17.6M, G&A $5.3M; net loss $21.5M vs $17.5M year ago.
- CFO Neha Krishnamohan to step down end of Dec, advisory role; successor search underway.

## SEC filing metadata
- accession: 0001193125-25-275867
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/0001193125-25-275867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/artv-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275867
- JSON: https://secwatch.observer/filing/0001193125-25-275867.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.